SCHEMBL209672

SCHEMBL209672

CC(c1ccncc1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.49
HTT P42858 2/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP3A4 P08684 2/20 0.47
CYP3A5 P20815 2/20 0.47
POLB P06746 1/20 0.46
ATM Q13315 1/20 0.46
TBK1 Q9UHD2 7/20 0.46
HRH3 Q9Y5N1 1/20 0.44
CHRM2 P08172 1/20 0.44
CHRM1 P11229 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8115616 0.86 CYP2D6 (0.57) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL3805489 0.86 CYP2D6 (0.57) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL210120 0.85 CYP3A4 (0.61) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL26199223 0.84 ALDH1A1 (0.51) HTTNPC1ALDH1A1MAPTMAPK1
SCHEMBL21399850 0.84 ALDH1A1 (0.51) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL28327837 0.84 ALDH1A1 (0.51) HTTNPC1ALDH1A1MAPTMAPK1
SCHEMBL660699 0.84 HTT (0.51) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL3837654 0.84 HTT (0.51) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL3837657 0.84 HTT (0.51) GPR119HTTNPC1ALDH1A1MAPT
SCHEMBL38661641 0.83 GPR119 (0.49) GPR119HTTNPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-7638531-B2 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 US disclosed
WO-2007075629-A2 PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS SCHERING CORPORATION (US) 2007-07-05 WO disclosed
WO-2007072017-A2 ENZYME INHIBITORS THE INSTITUTE OF CANCER RESEARCH (GB) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists HRH4, HRH3, HRH2 GPR119 43/4885HTT 979/4885NPC1 1270/4885
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA GPR119 3926/4885HTT 2611/4885NPC1 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.